好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

2025 Annual Meeting | Industry Therapeutic Update from Eli Lilly and Company: From the Case Files: Treating Early Symptomatic Alzheimer’s Disease

Monday 04/07/25
11:45 AM - 12:45 PM PDT Add To Calendar
San Diego Convention Center | 6B
This program will be presented in-person only
This program is not expected to be available in the meeting's On Demand product.
Industry Therapeutic Update
Jennifer R. Buczyner, MD, Aaron Ritter, MD
General Neurology, Aging, Dementia, and Behavioral Neurology
Join us for this engaging discussion between two experts as they discuss the treatment of early symptomatic Alzheimer’s disease through real patient cases. Their conversation will cover talking to patients about treatment, weighing risk and benefit, logistics of initiating treatment, managing treatment once started, and much more. Bring your questions and settle in for this compelling and educational presentation.
This program is NOT accredited for continuing education by any organization. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2025 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.
No CME available

Program Materials Program Evaluations

Event Timeline
11:45 AM - 12:45 PM PDT Speaker Industry Therapeutic Update from Eli Lilly and Company: From the Case Files: Treating Early Symptomatic Alzheimer’s Disease
Faculty Disclosures
Jennifer R. Buczyner, MD Dr. Buczyner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Buczyner has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Amgen. Dr. Buczyner has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eli Lilly. Dr. Buczyner has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion. Dr. Buczyner has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Abbvie. Dr. Buczyner has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biohaven.
Aaron Ritter, MD The institution of Dr. Ritter has received research support from NIH.